CorMedix Stock Rises on $75M Share Buyback Plan

TrustFinance Global Insights

Feb 02, 2026

2 min read

CorMedix Stock Rises on $75M Share Buyback Plan

## CorMedix Announces Share Repurchase Program CorMedix Inc. NASDAQ:CRMD saw its stock increase by 5.7% following the announcement of a $75 million share repurchase program. The company's board has authorized the buyback to run through December 31, 2027. ## Program Overview The biopharmaceutical firm plans to begin repurchasing shares as early as the first quarter of 2026. This decision is supported by a strong balance sheet, which reported approximately $150 million in cash and cash equivalents. The company currently has 79.3 million common shares outstanding. ## Market Impact and Strategy The buyback is viewed as a strategic move to return value to shareholders. CEO Joseph Todisco highlighted that the program maintains financial flexibility for future investments and potential inorganic growth opportunities. The plan allows for purchases through various methods, including open market transactions, and is not obligatory. ### Summary This share repurchase program signals management's confidence in the company's financial stability and expected cash flow. Market reaction was positive, and the flexible nature of the program allows the company to adapt to market conditions while rewarding its shareholders. #### FAQ **Q:** What is the total value of the CorMedix share buyback program? **A:** The program is authorized for up to $75 million of its outstanding common stock. **Q:** When is the share repurchase program effective until? **A:** The authorization extends through December 31, 2027. Source: [Investing.com](https://www.investing.com/news/stock-market-news/cormedix-stock-rises-after-announcing-75-million-share-buyback-plan-93CH-4479777)